, Volume 44, Supplement 4, pp 66–69 | Cite as

Round-Table Discussion



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Besenval M, Leray F, Delgado FM, Merle S, Krikorian A, et al. Navelbine (vinorelbine) tolerance in non-small-cell lung cancer. In Pierre Fabre Oncologie (Eds) Navelbine (vinorelbine). Update and new trends, pp. 185–194, John Libbey Eurotext, Montrouge, 1991Google Scholar
  2. Hansen HH. Chemotherapy of small-cell carcinoma: a review. Quarterly Journal of Medicine 63: 275–282, 1987PubMedGoogle Scholar
  3. Izzo J, Cvitkovic E, Toussaint G, Chabot F, et al. High activity and dose intensity (DI) relationship in advanced breast cancer (ABC) with continuous infusion (CIV) of navelbine. Proceedings of the Second Interface of Clinical and Laboratory Responses to Antitumour Drugs: Drugs and Microtubules, p. S6, Marseilles, 2–4 April 1992Google Scholar
  4. Østerlind K, Andersen PK. Prognostic factors in small-cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Research 46: 4189–4194, 1986PubMedGoogle Scholar
  5. Quoix E, Dietermann A, Charbonneau J, Boutin C, Meurice JC, et al. La chimiothérapie comportant du cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV? Résultats d’une étude randomisée. Bulletin du Cancer 78: 341–346, 1991PubMedGoogle Scholar
  6. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer — report of a Canadian multicenter randomized trial. Journal of Clinical Oncology 6: 633–641, 1988PubMedGoogle Scholar
  7. Woods RL, Williams CJ, Levi J, Page J, Bell D, et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small-cell lung cancer. British Journal of Cancer 61: 608–611, 1990PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1992

Personalised recommendations